Abstract:ObjectiveTo investigate the real-world viral response of chronic hepatitis C (CHC) patients receiving direct-acting antiviral agent (DAA) treatment and its effect on liver stiffness measurement (LSM) and aspartate aminotransferase-to-platelet ratio index (APRI). MethodsThe CHC patients who were consecutively admitted to Tianjin Third Central Hospital from April 1, 2018 to November 30, 2018 and received DAA treatment were enrolled, and all patients were treated with DAA (without interferon) for 12-24 weeks. Virologic response was evaluated at week 12 after treatment ended, and the changes of LSM and APRI from baseline to week 12 after treatment were compared. The Wilcoxon rank-sum test was used for comparison of continuous data between two groups. ResultsA total of 212 CHC patients were enrolled in our study, among whom 35.4% had liver cirrhosis, and the patients with genotype 1b, 2a, 3a, or 6a accounted for 75.0%, 18.4%, 4.2%, and 2.4%, respectively. Of all patients, 174 completed the course of DAA treatment and the 12-week follow-up, and among these patients, 98.3% achieved sustained virologic response (SVR) at the end of DAA treatment and 95.4% acquired SVR at week 12 after the treatment ended. Among the patients with genotype 1b, 2a, 3a, or 6a, 96.3%, 93.1%, 80.0%, and 100%, respectively, achieved SVR at week 12 after the treatment ended. There were significant reductions in LSM ［9.8 (6.9-16.3) kPa vs 11.4(77-19.1) kPa, Z=-2.5, P=0.012］ and APRI ［0.34 (0.25-0.64) vs 0.76 (0.56-2.25), Z=-6.6, P＜0.001］ from baseline to week 12 after the treatment ended. The patients were divided into groups according to the presence or absence of liver cirrhosis at baseline, and the results showed that from baseline to week 12 after treatment ended, the non-liver cirrhosis group had a significant reduction in LSM ［7.6 (6.6-10.7) kPa vs 8.8 (7.2-13.0) kPa, Z=-2.7, P=0.007］, while the liver cirrhosis group had no significant change in LSM ［17.4 (12.7-22.1) kPa vs 19.8 (12.8-24.9) kPa, Z=-1.4, P=0.152］. There was a significant reduction in APRI from baseline to week 12 after treatment ended in the liver cirrhosis group ［0.73 (0.52-1.34) vs 1.37 (0.80-2.11), Z=-3.4, P＜0001］ and the non-liver cirrhosis group ［0.29 (0.21-0.36) vs 0.54 (0.31-0.95), Z=-6.8, P＜0.001］. ConclusionIn this real-world study, CHC patients treated with DAA achieve a high overall virological response rate, with significant improvements in LSM and APRI at week 12 after treatment ends.

Direct Antiviral Agents Upregulate Natural Killer Cell Potential Activity in Chronic Hepatitis C Patients

Recovery of Natural Killer Cells is Mainly in Post-Treatment Period in Chronic Hepatitis C Patients Treated with Sofosbuvir Plus Ledipasvir

Restored Circulating Invariant NKT Cells Are Associated with Viral Control in Patients with Chronic Hepatitis B.

[Effects of Direct Antiviral Agent on the Frequency of Peripheral Blood Mononuclear Cells and Their Activating Factors Scd14s and CD163 in Patients with Chronic Hepatitis C].

Antiviral Treatment Alters the Frequency of Activating and Inhibitory Receptor-Expressing Natural Killer Cells in Chronic Hepatitis B Virus Infected Patients

Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals

Direct acting antivirals eradicate HCV from the liver quickly in people with HIV but do not fully reverse immune activation

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C

Influences of daclatasvir plus asunaprevir therapy on CD4+and CD8+T cell functions in patients with chronic hepatitis C

Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.

Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes

Changes in NK cells and regulatory T cells among patients with refractory chronic hepatitis C during antiviral treatment

Liver immune abnormalities persist after cure of Hepatitis C Virus by anti-viral therapy

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

Efficacy and Safety of Combined Directly Acting Antivirals for Treatment of Chinese Chronic Hepatitis C Patients in a Real-World Setting

High Frequencies of CD158b+ NK Cells Are Associated with Persistent Hepatitis C Virus Infections

Efficacy of direct-acting antiviral agents in treatment of chronic hepatitis C and its effect on liver stiffness and as-partate aminotransferase-to-platelet ratio index

Recovery of Circulating CD56dim NK Cells and the Balance of Th17/Treg after Nucleoside Analog Therapy in Patients with Chronic Hepatitis B and Low Levels of HBsAg

Direct Antiviral Agent Treatment Leads to Rapid and Significant Fibrosis Regression after HCV Eradication.

Direct-acting Antivirals Failed to Reduce the Incidence of Hepatocellular Carcinoma Occurrence in Hepatitis C Virus Associated Cirrhosis: A Real-World Study